Skip to content

Safety and Efficacy of the BrainPort™ Balance Device to Improve Balance in Bilateral Vestibular Hypofunction

A Clinical Study to Evaluate the Safety and Efficacy of the BrainPort™ Balance Device When Used to Improve Postural Control in Subjects With Bilateral Vestibular Disorders

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00254228
Enrollment
60
Registered
2005-11-15
Start date
2005-11-30
Completion date
2007-12-31
Last updated
2008-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vestibular Disease

Keywords

Balance, Vestibular, Electrotactile, BrainPort, Sensory substitution, Tongue

Brief summary

The purpose of this study is to determine whether the BrainPort™ balance device is safe and effective in the treatment of balance disorders in patients with Bilateral Vestibular Dysfunction.

Detailed description

People with Bilateral Vestibular Dysfunction (BVD) often experience disabling symptoms, greatly affecting their quality of life and ability to work. Current vestibular treatment does not always allow these patients to fully recover. Many patients either do not improve or reach a plateau with conventional vestibular rehabilitation, and still have difficulty with daily function. The BrainPort™ balance device is intended to provide information about head position to the brain through electrotactile stimulation of the tongue to improve balance in subjects with vestibular disorders. This study is a prospective, multi-center, randomized double-blinded study comparing the postural stability of BVD subjects using the BrainPort™ balance device to postural stability of control subjects using a sham device and respective baseline measures for each group. The primary objective of this study is to determine whether electrotactile stimulation of the tongue, using the BrainPort™ balance device, can improve postural stability, as measured by improvement in performance of the composite Computerized Dynamic Posturography using the NeuroCom® Sensory Organization Test in subjects with chronic bilateral vestibular dysfunction (BVD). The secondary objectives are to evaluate improvement in quality of life, as measured by the Activities Specific Balance Confidence (ABC) Scale, Dizziness Handicap Inventory (DHI), and the Dynamic Gait Index (DGI), and to demonstrate a decreased number of falls on the NeuroCom® Sensory Organization Test. In addition, we will monitor the number of falls that occur during subjects' normal activities of daily living. The long-term objective is to evaluate the safety and efficacy when the device is used over a one-year period.

Interventions

DEVICEElectrotactile sensory substitution

Sponsors

Wicab
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* Documented history of acquired bilateral vestibular dysfunction for a duration of at least one year which has been unsuccessfully treated or reached a plateau with conventional vestibular rehabilitation. * No greater than 2 successful attempts out of 6 on the NeuroCom Equitest Sensory Organization Tests 5 and 6. * Failure on the Rotary Chair Vestibulo-ocular Reflex (VOR) Test as evidenced by a gain of less than or equal to -2 standard deviations at frequencies of .025, and .05 Hz. * Normal corrected vision (20/40 or better). * Able to read and understand the informed consent form, and willing to sign the informed consent form. * Willing to complete all follow-up evaluations required by the study protocol. * Able to stand for a period of 20 minutes in a stationary position with weight evenly distributed without moderate pain, muscle cramping or numbness in the lower extremities.

Exclusion criteria

* Neurological disorders other than bilateral vestibular disorder, as determined by medical history and neurological screening procedure. * Current oral health problems as determined by health questionnaire and an examination of the oral cavity. * Cigarette smokers and those who use chewing tobacco. * Currently taking either benzodiazepine or barbiturate medication. * Any medical condition as determined by the health questionnaire that would interfere with performance on the postural stability evaluation tests. * Known neuropathies of tongue or skin tactile system. * Peripheral neuropathies of the lower extremities. * Prior exposure to BrainPort™ balance device (does not apply to control group subjects who cross over). * Subjects who are unwilling or unable to adhere to all study requirements, including completion of the training period, evaluation tests, and return to clinic for a follow-up visit. * Subjects who have undergone middle ear or other surgery with sacrifice or damage to the chorda tympani, lingual, or hypoglossal nerve. * Subjects who have an implanted device such as a pacemaker or defibrillator. * If the subject is female, she is pregnant. * If the subject is unwilling to discontinue medications for dizziness or imbalance 48 hours prior to beginning the study.

Design outcomes

Primary

MeasureTime frame
Computerized Dynamic Posturography using the NeuroCom Sensory Organization Test (SOT) composite score, taken at baseline, 1 week, 8 weeks and 12 months.

Secondary

MeasureTime frame
Dizziness Handicap Inventory (DHI)
Dynamic Gait Index (DGI)
Activities-specific Balance Confidence Scale (ABC)
Functional Objective Tests i.e. standing with eyes closed, on one leg, etc.
All tests taken at baseline, 1 week, 8 weeks and 12 months.
Number of falls on the NeuroCom SOT

Countries

United Kingdom, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026